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Abstract
Background: Ischemic preconditioning and postconditioning are the novel strategies of attaining 
cardioprotection against ischemia/reperfusion (I/R) injury. Previous studies suggested the role of opioid 
pathway, however the class of opioid receptors responsible for this effect in humans remains unknown. 
The aim of the study was to assess the influence of opioids on simulated I/R injury outcomes in the hu-
man myocardium.
Methods: Trabeculae of the human right atrium were electrically driven in organ bath and subjected 
to simulated I/R injury. Morphine (10–4M, 10–5M, 10–6M) or d-opioid receptor agonist DADLE (10–8M, 
10–7M, 10–6M) was used at the time of re-oxygenation. Additional trabecula was subjected to hypoxia 
protocol only (Control). Contractive force of the myocardium was assessed as the maximal force of  
a contraction (Amax), the rate of rise of the force of a contraction (Slope L) and relaxation as the rate of 
decay of the force of a contraction (Slope T).
Results: Application of morphine 10–4M resulted in increase of Amax, Slope L and Slope T during re-
oxygenation period as compared to Control (77.99 ± 1.5% vs. 68.8 ± 2.2%, p < 0.05; 45.72 ± 2.9% vs. 
34.12 ± 5.1%, p < 0.05; 40.95 ± 2.5% vs. 32.37 ± 4.3%, p < 0.05). Parameters were not significantly 
different in the lower morphine concentrations. Application of DADLE 10–6M resulted in decrease of 
Amax and Slope L as compared to Control (68.13 ± 5.5% vs. 76.62 ± 6.6%, p < 0.05; 28.29 ± 2.2 
vs. 34.80 ± 3.9%, p < 0.05).
Conclusions: At re-oxygenation, morphine improves systolic and diastolic function of the human myo-
cardium in the dose-dependent manner. Delta-opioid receptor stimulation attenuates systolic function 
of human heart muscle which remains in contrast to previous reports with animal models of I/R injury. 
(Cardiol J 2017; 24, 4: 419–425)
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Introduction
The restoration of coronary flow is neces-
sary to reduce ischemic myocardial damage and 
may save some degree of contractile function to 
the ischemic heart muscle. However, in the early 
reperfusion period, an additional damage of car-
diac tissue has been observed in the mechanism 
known as ischemia/reperfusion (I/R) injury which 
in clinical settings manifests as the decrease of 
potential benefits of reperfusion. Sequences of 
brief ischemia periods applied before (precondi-
tioning [IPC]) or after (postconditioning [POC]) 
the coronary occlusion are well documented to 
trigger protective mechanisms to the heart muscle 
against I/R injury. These phenomena are widely 
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demonstrated in many species in in vitro and in vivo 
studies [1–4]. The mechanisms underlying IPC or 
POC are still not clarified, but strong experimen-
tal evidence suggests that opioids may be part of 
the endogenous cardioprotective response to I/R 
injury and trigger intracellular enzyme cascades 
leading ultimately to closure of the mitochondrial 
permeability transition pore (mPTP) responsible 
for induction of cell damage [5]. The functional 
effects of opioids are mediated via activation of 
respective opioid receptors (OR). Morphine was 
the first opioid with proven cardioprotective ef-
fect [6]. More recently, several investigators have 
demonstrated in an animal model of I/R injury that 
beneficial effect is mediated via the d-OR pathway 
[7–9]. However, the class of ORs responsible for 
this effect in humans remains unknown [10]. Bell et 
al. [11] have shown that OR activation before pro-
longed hypoxia preserved the force of contraction 
of isolated human myocardium. The current study 
was taken to delineate the effect of different doses 
of OR modulators (non-selective opioid receptor 
agonist: morphine, selective d-opioid receptor 
agonist D-Ala D-Leu–Encephalin [DADLE]) ap-
plied at the reperfusion on the function of human 
ischemic myocardium.
Methods
The experiments were performed on muscu-
lar trabeculae obtained from the right heart atrial 
appendages of 67 consecutive patients (39 males/ 
/28 females) subjected to the coronary artery 
bypass surgery. Patients diagnosed with the sig-
nificant valvular heart disease or with severe heart 
failure therapy were excluded from the study. Mean 
ejection fraction was 52.3 ± 2.39%. No trabeculae 
were excluded in this study.
The fragments of the human right heart atria 
were immediately transported from the cardiac 
surgery room to the laboratory in an ice-cold 
Krebs-Henseleit solution ([mmol/L]: NaCl 118.0, 
KCl 4.70, CaCl2 1.52, MgSO4 1.64, NaHCO3 24.88, 
KH2PO4 1.18, glucose 11.0, and sodium pyruvate 
2.0; pH 7.4). Two muscular trabeculae were dis-
sected from the right heart atria and incubated 
in two separate organ baths (Schuler Organbath, 
Hugo Sachs Elektronik, March-Hugstetten, Ger-
many [HSE]) both filled with Krebs-Henseleit 
solution warmed up to 37°C. To avoid core hypoxia, 
trabeculae included in the study had a cross-sec-
tional area of less than 1 mm in diameter.
The Local Bioethics Committee approval 
for the use of human tissue was obtained (NN- 
-6501/98/07) and individual patient consent from 
all patients was waived. All experiments were 
performed according to the principles stated in the 
Declaration of Helsinki. Morphine was obtained 
from Polfa S.A. DADLE was obtained from Sigma 
Aldrich Co.
Protocols
Two trabeculae from each patient were always 
studied simultaneously and exposed to hypoxia 
protocol including: 60 min of hypoxia (incubation 
in Krebs-Henseleit buffer deprived of glucose and 
pyruvate, and saturated with 95% argon and 5% 
carbon dioxide) with subsequent 60 min of re-
oxygenation (incubation in Krebs-Henseleit buffer 
saturated with 95% oxygen and 5% carbon dioxide). 
The buffer was replaced every 15 min, except the 
time of hypoxia. To determine the effects of opioid 
cardioprotection, 3 doses of morphine or DADLE 
were administered. Morphine (10–4M, 10–5M, or 10–6M) 
or DADLE (10–8M, 10–7M or 10–6M) were used at 
the time of re-oxygenation. The second trabecula 
was subjected only to hypoxia protocol (Control). 
Additional trabeculae were exposed to 120-min 
non-hypoxic stimulation in Krebs-Henseleit buffer 
saturated with 95% oxygen and 5% carbon dioxide 
(Sham). Every trabecula was stretched to 90% 
of its optimal tension strength, according to the 
Frank-Starling relationship and all trabeculae were 
driven throughout experiments with 1 Hz 50 ms2 
stimuli using platinum field electrodes and a stimu-
lator (Type 215, HSE). The systolic function of 
every trabecula was recorded with the use of F30 
isometric force transducer (Type 372, HSE). The 
signal was enhanced with a bridge amplifier (Type 
336, HSE) and recorded by a PowerLab/4SP system 
and analyzed off-line using Chart software (AD 
Instruments, Chalgrove, Oxfordshire, UK). Each 
experimental protocol was completed with 10 μM 
of norepinephrine (NE) application to assess the 
viability of trabeculae. The contractive force of 
the myocardium assessed as the maximal force of 
a contraction (Amax), the rate of rise of the force 
of a contraction (Slope L) and relaxation assessed 
as the rate of decay of the force of a contraction 
(Slope T) was obtained in 5th, 10th, 15th, 30th, 45th 
and 60th min of re-oxygenation and after the NE 
application.
Data analysis
The results were presented as the percent 
of values obtained before experimental protocol 
application. All continuous data were normally 
distributed and presented as a mean ± standard 
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error (SE). Two-way analysis of variance 
(ANOVA) followed by Holm-Sidack test was used 
to compare the results of values from 5th to 60th 
min of re-oxygenation (SigmaPlot 10.0.1.2). A p 
value less than 0.05 was considered statistically 
significant.
Results
There were no significant differences in age, 
sex and pharmacotherapy between the patients 
from whom the trabeculae were taken and were 
subjected to morphine, DADLE, Control protocols.
Application of morphine 10–4M resulted in 
increase of Amax, Slope L and Slope T during 
re-oxygenation period as compared to Control. 
Parameters were not significantly different in the 
lower morphine concentration group. Application 
of DADLE 10–6M resulted in decrease of Amax and 
Slope L as compared to Control with no significant 
differences for Slope T. In the lower DADLE con-
centration (10–7M), we observed significant decrease 
of Amax vs. Control, with no differences for Slope 
L, Slope T. Application of DADLE 10–8M resulted in 
decrease of Slope L as compared to Control with no 
significant differences for Amax, Slope T.
All systolic and diastolic parameters were 
significantly higher for non-hypoxic stimulation 
(Sham) as compared to morphine, DADLE and 
Control protocols during re-oxygenation period 
and after NE application.
All detailed results are included in Table 1 and 
visualized in Figures 1 and 2.
Discussion
Morphine has received research interest par-
ticularly for pain treatment. The European Society 
of Cardiology guidelines recommend administra-
tion of intravenous morphine to relieve pain in 
acute cardiac infarction [12]. Moreover, according 
to American Heart Association guidelines, mor-
phine has a beneficial effect on non-ST elevation 
acute coronary syndrome (NSTE-ACS) [13]. Mor-
phine is a part of pulmonary edema treatment due 
to the anxiolytic and vasodilatory properties. Non-
specific depression of the central nervous system is 
probably an important factor for hemodynamics in 
Table 1. Parameters of function of human myocardium subjected to morphine/DADLE, Sham or  
Control protocol. 
Protocol N Amax [%] Slope L [%] Slope T [%]
Morphine 10–4M 9 77.99 ± 1.5 45.72 ± 2.9 40.95 ± 2.5
Control 9 68.8 ± 2.2 34.12 ± 5.1 32.37 ± 4.3
p < 0.05 < 0.05 < 0.05
Morphine 10–5M 10 72.78 ± 2.0 40.81 ± 2.3 35.73 ± 2.0
Control 10 68.96 ± 2.0 35.52 ± 2.3 32.30 ± 2.0
p 0.239 0.113 0.153
Morphine 10–6M 8 68.69 ± 1.4 35.57 ± 1.7 32.14 ± 2
Control 8 68.52 ± 2.1 37.04 ± 2.9 32.47 ± 3.2
p 0.849 0.524 0.884
DADLE 10–6M 7 68.13 ± 5.5 28.29 ± 2.2 24.50 ± 2.1
Control 7 76.62 ± 6.6 34.80 ± 3.9 28.85 ± 3.7
p < 0.05 < 0.05 0.487
DADLE 10–7M 15 61.57 ± 1.6 34.31 ± 1.8 27.14 ± 1.6
Control 15 67.71 ± 2.8 34.29 ± 3.2 30.76 ± 2.7
p < 0.05 0.812 0.463
DADLE 10–8M 9 71.74 ± 1.4 35.85 ± 3.3 34.75 ± 3.9
Control 9 75.07 ± 2.5 45.47 ± 5.8 37.53 ± 5.6
p   0.374 < 0.05 0.413
Sham 9 89.25 ± 2.2 87.46 ± 2.5 85.52 ± 3.1
Data are presented as mean ± standard error and compared by two way analysis of variance with Holm-Sidack post hoc test. P < 0.05  
marked as significantly different from value in Control (intergroup comparison); Amax — maximal force of a contraction; DADLE —  
D-Ala D-Leu–Encephalin; Slope L — rate of rise of the force of a contraction; Slope T — rate of decay of the force of a contraction
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Figure 1. The effect of opioid receptor modulators on function of human myocardium during the re-oxygenation pe-
riod. Figures present analysis of the contractive function as the maximal force of a contraction (Amax; A) and the rate 
of rise of the force of a contraction (Slope L; B),  and assessment of the relaxation as the rate of decay of the force of 
a contraction (Slope T; C); *p < 0.05 marked as significantly different from value in Control (intergroup comparison).
Figure 2. Function of the human myocardium within 5th and 60th min of re-oxygenation period, subjected to morphine 
(M) 10–4M (A) or D-Ala D-Leu–Encephalin (DADLE) 10–8M (B) compared with Sham or Control protocols. Figures pre-
sent parameter of the contractive function of the myocardium — rate of rise of the force of a contraction (Slope L). 
Sham presented non-hypoxic conditions.
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pulmonary edema [14]. Opioids are also commonly 
used in a perioperative period of coronary artery 
by-pass grafting (CABG).
The results showed that morphine adminis-
tered at the onset of reperfusion improved functional 
recovery in human heart tissue. We observed the 
maximal protective effect of morphine at a 10–4M 
concentration. Moreover, we noted that activation of 
d-OR led to decrease of myocardial systolic function.
Previous studies on the influence of opioids 
in human cardiac tissue utilized mainly the OR 
modulators applied before the lethal hypoxic period 
[8, 15]. The novelty of our study is that morphine 
and DADLE were applied at the reperfusion that 
makes the study protocol compatible with usual 
clinical circumstances. Our study was performed 
on isolated fragments of human right atria. For 
functional studies, atrial tissue sampling can avoid 
the influence of confounding factors, like the effect 
of drugs or the presence of collateral circulation. In 
this model, we did not assess the infarct size as in 
previous papers, but the differences of contractility 
as a functional consequences of cardiac ischemia.
Experimental data from multiple species 
indicate that OR activity is implicated in cardio-
protection. However, there is some doubt regard-
ing the OR subtype primarily responsible for the 
cardioprotective effect.
Beneficial effect of selective d-OR agonists has 
been confirmed in a variety of models including rat 
cardiomyocytes [16] in situ and ex vivo rat hearts 
[17], rabbit model [18], or canine [19]. Otherwise, 
studies with animal models reported that k-OR but 
not d-OR stimulation provided both infarct size 
limiting and antiarrhythmic effect [20, 21]. More 
recently, Tsai et al. [22] reported that the protective 
effect may be caused by the activation of OR signal-
ing pathway with the highest influence of k-OR and 
the lowest of µ-OR stimulation. In contrast, some 
investigators reported in the isolated rat hearts, 
detrimental influence of k-OR activation [23]. 
Based on the previous studies showing that d-OR 
and k-OR, but not µ-ORs were present in rat cardiac 
tissue [24], investigators concluded that stimula-
tion of d-OR and k-OR conferred cardioprotection. 
Otherwise, beneficial effect of selective µ-OR ago-
nist — remifentanil in rats remains unclear [25]. 
Whether this effect is involved in cross-talk with 
other ORs or roles of extracardiac µ-ORs, remains 
to be determined. Although, µ-ORs are present in 
human cardiomyocytes. Indeed, cardioprotective 
effect of µ-OR stimulation in humans, confirmed 
in the clinical study with remifentanil administered 
in patients subjected to CABG [26].
We presented morphine concentration of 
10–4M to be cardioprotective. Lesser concentra-
tions did not show protective effect. According to 
the previous reports, in the rabbit heart, 3 mg/kg 
of morphine is required to achieve protective effect 
[27]. This dose is much higher than clinically used: 
in humans, the standard dose is about 0.14 mg/kg. 
Interestingly, administration of helium by inhala-
tion in rabbits can reduce the effective threshold 
dose of morphine to 100 μg/kg. Noble gases, 
through the activation of a RISK kinase pathway, 
can lead to the closure of mPTP channels during 
reperfusion period. Moreover, this effect is blocked 
by naloxone [28]. Similar results was documented 
with the co-application of morphine and volatile 
anesthetics like isoflurane [29] and sevoflurane 
[30]. Further study on cardioprotective effect of 
inhaled drugs may bring interesting conclusions.
Although many studies are focused on car-
dioprotective effect of peripheral OR stimulation, 
there are also several reports outlining that the 
cardioprotective effects of opioids are mediated 
through central OR stimulation [31]. Intrathecal 
infusion of morphine resulted in the reduction of 
infarct size in rats and the use of naloxone methio-
dide, not penetrating the brain-blood barrier did 
not affect the protective effect [32]. Furthermore, 
protective effect was achieved with morphine in 
doses of 0.01–1 mg/kg comparable with the effect 
observed with intravenous administration of mor-
phine in high dose 300 mg/kg [32]. This phenom-
enon results probably from interaction with central 
ORs, longer opioid half-life in the cerebro-spinal 
fluid and slow penetration of the opioid through the 
blood-brain barrier. Thus, intrathecal opioids allow 
the use of a lower dose to achieve the similar effect 
with reduced risk of complications [33].
The differences of species in animal model 
used in studies might account for the discrepancies 
in results. In contrast to in vivo studies, isolated 
cardiac tissue has a limited period of biological 
stability. The viability of the cardiac tissue differs 
depending on the animal model, for example, in 
rats, application of 30–40 min of ischemia causes 
damage to 50% of tissue and in pigs, similar ef-
fect is observed after 90 min of ischemia. In our 
study, due to limited time of heart tissue stability, 
we analyzed no more than 60 min period after 
re-oxygenation. In human atrial and ventricular 
muscle, µ-OR and d-OR are presented, while k-OR 
are negligible. In adult rats, µ-OR are absent. Most 
of the studies were performed on young animals, 
whereas intrinsic protective tolerance against 
I/R injury may fail with age in humans [34, 35]. 
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It was difficult to offer a feasible explanation due 
to cross-talk between OR-agonists and other 
receptor/transduction systems. For example, the 
influence of interleukin 2 (IL-2) on the contrac-
tion appears to be mediated via the cardiac k-OR 
and the post-receptor signal transduction pathway 
includes a pertussis toxin sensitive G protein and 
phospholipase C. This effect in isolated rat heart 
was completely blocked by k-OR but no d-OR 
antagonists [36]. There are also reports providing 
evidence that receptors coupled with G protein 
(GPCRs) form heterodimers resulting in novel 
ligand binding properties. Furthermore, complexed 
µ-OR and d-OR have been shown to be sensitive 
to ligands selective for d2-OR, as well as all OR 
types form hetero-oligomers [36]. Moreover, ORs 
appear to dimerize with other GRCRs, e.g. a2- 
and b2-adrenergic receptors [37] or somatostatin 
receptors [38]. Thus, the OR dimerization results 
in altered pharmacological characteristics espe-
cially associated with ligand binding. In addition, 
the discrepancies between researches may result 
from the fact that morphine works in not yet fully 
understood non-receptor mediated mechanism via 
modulation of ion channels [35].
Limitations of the study
The results must be interpreted within the 
limitations of the methodology. The construction 
of our experiment assumes a control group derived 
from the same patient and the same factors poten-
tially affecting the test. We must note, however 
that simulated ischemic model differs from in vivo 
condition. In our experiment, we utilized the buffer, 
thus there we no elements transporting or bind-
ing opioids, like peptides. Based on experiments 
on animal models of ischemia, we could conclude 
that administration of d-OR agonist is sufficient 
to achieve a cardioprotective effect, with avoiding 
the side effects of central µ-OR stimulation, e.g. 
depression of the respiratory center. Our results 
present detrimental effect of d-OR agonism. More-
over, in humans, protective effect of opioids might 
depend on more complicated mechanism than only 
one type of OR stimulation.
Conclusions
At re-oxygenation, morphine improves systol-
ic and diastolic function of the human myocardium 
in a dose-dependent manner. Delta-opioid receptor 
stimulation attenuates systolic function of the hu-
man heart muscle, which remains in contrast to the 
previous reports with animal model of I/R injury.
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